Inimmune’s Chief Scientific and Strategy Officer, Dr. Jay Evans, will participate in BioJapan and provide a company update on clinical programs on Friday, October 13 in Yokohama, Japan
MISSOULA, MT, October 10, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at BioJapan (https://jcd-expo.jp/en/). New immunotherapy drugs and vaccine technologies have shown great promise in the treatment of allergy, cancer, […]
Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6
MISSOULA, Montana, September 26, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a speaker at the International Precision Vaccines Conference (https://precisionvaccines2023.com/) in Rome, Italy on October 5-6. The International Precision Vaccine Conference […]
Inimmune to Present on Novel Adjuvants at the 17th Vaccine Congress on September 26th, 2023
MISSOULA, MT, September 21, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a plenary presentation at the upcoming 17th Vaccine Congress in Glasgow, Scotland September 24-27th. The event brings together leading […]
Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Milestone marks transition of Inimmune Corporation to a clinical-stage company MISSOULA, Montana, August 2, 2023 – Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, today announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential […]
Development of Novel STING Agonists as Vaccine Adjuvants
MISSOULA, Montana, March 29, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its Investigator, Omer Rasheed, Ph.D., will participate and present a poster (P087) at the upcoming ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023 in Boston entitled “Development of Novel STING Agonists as Vaccine Adjuvants” […]
Inimmune attends BIO International Convention and provides an update on company programs and transition to a clinical stage biotech company.
MISSOULA, Montana, June 5, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will provide an update on company programs and clinical trials on May 5th at BIO International Convention in Boston, MA […]
Inimmune to Play a Key Role at the World Vaccine Congress
MISSOULA, Montana, March 29, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event. Dr. Evans will serve […]
Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies
MISSOULA, Montana, February 2, 2022 – Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small Business Innovation Research (SBIR) Direct to Phase II program to advance a novel adjuvant and delivery system for vaccines. Adjuvants […]
Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital
MISSOULA, Montana, February 2, 2022 – Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company’s first outside investment. The round was led by Two Bear Capital, www.twobearcapital.com, a new firm based in Whitefish, Montana. Two Bear Capital Founder […]
Inimmune Welcomes New Chief Medical Officer
January 7th, 2022 MISSOULA, Montana, February 2, 2022 – After receiving his medical degree from Loma Linda University and completing an Internal Medicine Residency at Mayo Clinic, Dr. Ruckle served as the founding Medical Director at Northwest Kinetics in Tacoma, WA, from 1995 to 2000. He then led Phase I development at Radiant Research Honolulu […]
